Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Icheva, V; Kayser, S; Wolff, D; Tuve, S; Kyzirakos, C; Bethge, W; Greil, J; Albert, MH; Schwinger, W; Nathrath, M; Schumm, M; Stevanovic, S; Handgretinger, R; Lang, P; Feuchtinger, T; .
Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1-Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation.
J CLIN ONCOL. 2013; 31(1): 39-48.
Doi: 10.1200/JCO.2011.39.8495
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Schwinger Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Purpose Reactivation of Epstein-Barr virus (EBV) after allogeneic stem-cell transplantation (SCT) can lead to severe life-threatening infections and trigger post-transplantation lymphoproliferative disease (PTLD). Since EBV-specific T cells could prevent PTLD, cellular immunotherapy has been a promising treatment option. However, generation of antigen-specific T-cell populations has been difficult within a short time frame. Patients and Methods To improve availability in urgent clinical conditions, we developed a rapid protocol for isolation of polyclonal EBV nuclear antigen 1 (EBNA-1) -specific T cells by using an interferon gamma (IFN-gamma) capture technique. Results We report on the use of adoptive transfer of EBNA-1-specific T cells in 10 pediatric and adult patients with EBV viremia and/or PTLD after SCT. No acute toxicity or graft-versus-host disease (GVHD) of more than grade 2 occurred as a result of adoptive T-cell transfer. In vivo expansion of transferred EBNA-1-specific T cells was observed in eight of 10 patients after a median of 16 days following adoptive transfer that was associated with clinical and virologic response in seven of them (70%). None of the responders had EBV-associated mortality. Within clinical responders, three patients were disease free by the day of last follow-up (2 to 36 months), three patients died of other infectious complications, and one patient died as a result of relapse of malignancy. EBV-related mortality was observed in two of 10 patients, and another patient had ongoing viremia without clinical symptoms at last follow-up. Conclusion Adoptive ex vivo transfer of EBNA-1-specific T cells is a feasible and well-tolerated therapeutic option, representing a fast and efficient procedure to achieve reconstitution of antiviral T-cell immunity after SCT. J Clin Oncol 31:39-48. (c) 2012 by American Society of Clinical Oncology
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adoptive Transfer -
- Adult -
- Child -
- Child, Preschool -
- Combined Modality Therapy -
- Epstein-Barr Virus Infections - immunology Epstein-Barr Virus Infections - metabolism Epstein-Barr Virus Infections - virology
- Epstein-Barr Virus Nuclear Antigens - metabolism
- Female -
- Follow-Up Studies -
- Graft vs Host Disease - immunology Graft vs Host Disease - mortality Graft vs Host Disease - prevention & control
- Herpesvirus 4, Human - physiology
- Humans -
- Interferon-gamma - metabolism
- Lymphoproliferative Disorders - etiology Lymphoproliferative Disorders - metabolism Lymphoproliferative Disorders - therapy
- Male -
- Middle Aged -
- Neoplasm Staging -
- Neoplasms - complications Neoplasms - therapy
- Prognosis -
- Stem Cell Transplantation - adverse effects
- T-Lymphocytes - immunology T-Lymphocytes - metabolism T-Lymphocytes - transplantation
- Transplantation, Homologous -
- Viral Load - immunology
- Young Adult -